Syndecan-1, an indicator of endothelial glycocalyx degradation, predicts outcome of patients admitted to an ICU with COVID-19.

Dong ZhangLiubing LiYu ChenJie MaYanli YangSurita AodengQiuju CuiKedi WenMeng XiaoJing XieYingchun XuYongzhe Li

Published in: Molecular medicine (Cambridge, Mass.) (2021)

COVID-19 patients with high levels of Syndecan-1 develop more serious endothelial damage and inflammatory reactions, and have increased mortality. Syndecan-1 has potential for use as a marker for progression or severity of COVID-19. Protecting the glycocalyx from destruction is a potential treatment for COVID-19.

Keyphrases

coronavirus disease
sars cov
oxidative stress
respiratory syndrome coronavirus
intensive care unit
cardiovascular disease
coronary artery disease
cardiovascular events
acute respiratory distress syndrome
extracorporeal membrane oxygenation
replacement therapy